Cargando…
Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker
BACKGROUND AND PURPOSE: Early diagnosis of amnestic mild cognitive impairment (aMCI) and timely management to delay the onset of Alzheimer's disease (AD) would benefit patients. Pathological metabolic changes of excitatory/inhibitory neurotransmitters and abnormal protein deposition in the hipp...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995585/ https://www.ncbi.nlm.nih.gov/pubmed/36908797 http://dx.doi.org/10.3389/fnins.2023.1089300 |
_version_ | 1784902856240791552 |
---|---|
author | Chen, Xin Gong, Tao Chen, Tong Xu, Changyuan Li, Yuchao Song, Qingxu Lin, Liangjie Oeltzschner, Georg Edden, Richard A. E. Xia, Zhangyong Wang, Guangbin |
author_facet | Chen, Xin Gong, Tao Chen, Tong Xu, Changyuan Li, Yuchao Song, Qingxu Lin, Liangjie Oeltzschner, Georg Edden, Richard A. E. Xia, Zhangyong Wang, Guangbin |
author_sort | Chen, Xin |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Early diagnosis of amnestic mild cognitive impairment (aMCI) and timely management to delay the onset of Alzheimer's disease (AD) would benefit patients. Pathological metabolic changes of excitatory/inhibitory neurotransmitters and abnormal protein deposition in the hippocampus of aMCI may provide a new clue to imaging diagnosis. However, the diagnostic performance using these hippocampal metabolite measurements is still unclear. We aimed to quantify right hippocampal glutamate–glutamine (Glx) and gamma-aminobutyric acid (GABA) levels as well as protein-based amide proton transfer-weighted (APTw) signals of patients with aMCI and investigate the diagnostic performance of these metabolites. METHODS: In this cross-sectional study, 20 patients with aMCI and 20 age- and gender-matched healthy controls (HCs) underwent MEGA Point Resolved Spectroscopy (MEGA-PRESS) and APTw MR imaging at 3 T. GABA+, Glx, and APTw signals were measured in the right hippocampus. The GABA+ levels, Glx levels, Glx/GABA+ ratios, and APTw values were compared between the HCs and aMCI groups using the Mann–Whitney U test. Binary logistic regression and receiver operating characteristic (ROC) curve analyses were used to evaluate MEGA-PRESS and APTw parameters' diagnostic performance. RESULTS: Compared with HCs, patients with aMCI had significantly lower Glx levels in the right hippocampus (7.02 ± 1.41 i.u. vs. 5.81 ± 1.33 i.u., P = 0.018). No significant changes in the GABA+ levels were observed in patients with aMCI (HCs vs. aMCI: 2.54 ± 0.28 i.u. vs. 2.47 ± 0.36 i.u., P = 0.620). In addition, Glx/GABA+ ratios between the two groups (HCs vs. aMCI: 2.79 ± 0.60 vs. 2.37 ± 0.55, P = 0.035) were significantly different. Compared with HCs, patients with aMCI showed higher APTw values in the right hippocampus (0.99 ± 0.26% vs. 1.26% ± 0.28, P = 0.006). The ROC curve analysis showed that Glx, GABA+, Glx/GABA+, and APTw values had an area under the curve (AUC) of 0.72, 0.55, 0.70, and 0.75, respectively, for diagnosing aMCI. In the ROC curve analysis, the AUC of the combination of the parameters increased to 0.88, which is much higher than that observed in the univariate analysis (P < 0.05). CONCLUSION: The combination of right hippocampal Glx levels and APTw values improved the diagnostic performance for aMCI, indicating it as a promising combined imaging diagnostic marker. Our study provided a potential imaging diagnostic strategy of aMCI, which may promote early detection of aMCI and facilitate timely intervention to delay the pathological progress toward AD. |
format | Online Article Text |
id | pubmed-9995585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99955852023-03-10 Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker Chen, Xin Gong, Tao Chen, Tong Xu, Changyuan Li, Yuchao Song, Qingxu Lin, Liangjie Oeltzschner, Georg Edden, Richard A. E. Xia, Zhangyong Wang, Guangbin Front Neurosci Neuroscience BACKGROUND AND PURPOSE: Early diagnosis of amnestic mild cognitive impairment (aMCI) and timely management to delay the onset of Alzheimer's disease (AD) would benefit patients. Pathological metabolic changes of excitatory/inhibitory neurotransmitters and abnormal protein deposition in the hippocampus of aMCI may provide a new clue to imaging diagnosis. However, the diagnostic performance using these hippocampal metabolite measurements is still unclear. We aimed to quantify right hippocampal glutamate–glutamine (Glx) and gamma-aminobutyric acid (GABA) levels as well as protein-based amide proton transfer-weighted (APTw) signals of patients with aMCI and investigate the diagnostic performance of these metabolites. METHODS: In this cross-sectional study, 20 patients with aMCI and 20 age- and gender-matched healthy controls (HCs) underwent MEGA Point Resolved Spectroscopy (MEGA-PRESS) and APTw MR imaging at 3 T. GABA+, Glx, and APTw signals were measured in the right hippocampus. The GABA+ levels, Glx levels, Glx/GABA+ ratios, and APTw values were compared between the HCs and aMCI groups using the Mann–Whitney U test. Binary logistic regression and receiver operating characteristic (ROC) curve analyses were used to evaluate MEGA-PRESS and APTw parameters' diagnostic performance. RESULTS: Compared with HCs, patients with aMCI had significantly lower Glx levels in the right hippocampus (7.02 ± 1.41 i.u. vs. 5.81 ± 1.33 i.u., P = 0.018). No significant changes in the GABA+ levels were observed in patients with aMCI (HCs vs. aMCI: 2.54 ± 0.28 i.u. vs. 2.47 ± 0.36 i.u., P = 0.620). In addition, Glx/GABA+ ratios between the two groups (HCs vs. aMCI: 2.79 ± 0.60 vs. 2.37 ± 0.55, P = 0.035) were significantly different. Compared with HCs, patients with aMCI showed higher APTw values in the right hippocampus (0.99 ± 0.26% vs. 1.26% ± 0.28, P = 0.006). The ROC curve analysis showed that Glx, GABA+, Glx/GABA+, and APTw values had an area under the curve (AUC) of 0.72, 0.55, 0.70, and 0.75, respectively, for diagnosing aMCI. In the ROC curve analysis, the AUC of the combination of the parameters increased to 0.88, which is much higher than that observed in the univariate analysis (P < 0.05). CONCLUSION: The combination of right hippocampal Glx levels and APTw values improved the diagnostic performance for aMCI, indicating it as a promising combined imaging diagnostic marker. Our study provided a potential imaging diagnostic strategy of aMCI, which may promote early detection of aMCI and facilitate timely intervention to delay the pathological progress toward AD. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995585/ /pubmed/36908797 http://dx.doi.org/10.3389/fnins.2023.1089300 Text en Copyright © 2023 Chen, Gong, Chen, Xu, Li, Song, Lin, Oeltzschner, Edden, Xia and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Chen, Xin Gong, Tao Chen, Tong Xu, Changyuan Li, Yuchao Song, Qingxu Lin, Liangjie Oeltzschner, Georg Edden, Richard A. E. Xia, Zhangyong Wang, Guangbin Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker |
title | Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker |
title_full | Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker |
title_fullStr | Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker |
title_full_unstemmed | Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker |
title_short | Altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: A novel combined imaging diagnostic marker |
title_sort | altered glutamate–glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: a novel combined imaging diagnostic marker |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995585/ https://www.ncbi.nlm.nih.gov/pubmed/36908797 http://dx.doi.org/10.3389/fnins.2023.1089300 |
work_keys_str_mv | AT chenxin alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT gongtao alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT chentong alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT xuchangyuan alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT liyuchao alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT songqingxu alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT linliangjie alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT oeltzschnergeorg alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT eddenrichardae alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT xiazhangyong alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker AT wangguangbin alteredglutamateglutamineandamideprotontransferweightedvaluesinthehippocampusofpatientswithamnesticmildcognitiveimpairmentanovelcombinedimagingdiagnosticmarker |